-

Law Offices of Frank R. Cruz Encourages FS KKR Capital Corp. (FSK) Shareholders To Inquire About Securities Fraud Class Action

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of shareholders who purchased or otherwise acquired FS KKR Capital Corp. (“FS KKR Capital” or the “Company”) (NYSE: FSK) securities between May 8, 2024 and February 25, 2026, inclusive (the “Class Period”). FS KKR Capital investors have until July 3, 2026 to file a lead plaintiff motion.

Law Offices of Frank R. Cruz Encourages FS KKR Capital Corp. (FSK) Shareholders To Inquire About Securities Fraud Class Action

Share

IF YOU SUFFERED A LOSS ON YOUR FS KKR CAPITAL CORP. (FSK) INVESTMENTS, CLICK HERE TO SUBMIT A CLAIM TO POTENTIALLY RECOVER YOUR LOSSES IN THE ONGOING SECURITIES FRAUD LAWSUIT.

You can also contact the Law Offices of Frank R. Cruz to discuss your legal rights by email at info@frankcruzlaw.com, by telephone at (310) 914-5007, or visit our website at www.frankcruzlaw.com.

What Happened?

On August 6, 2025, after the market closed, the Company reported second quarter 2025 earnings, revealing that the Company’s net asset value had declined to $21.93 per share, down $1.44, or 6.2% from the prior quarter, and the total fair value of investments fell $474 million, to $13,648 million. Moreover, the Company reported earnings (loss) per share of negative $0.75, down $1.18 or 274.4% from the prior quarter, and a total net realized and unrealized loss per share of negative $1.36, down $1.12 or 466.7% from the prior quarter. Further, investments on non-accrual status rose to 3.0% and 5.3% of the total investment portfolio at fair value and amortized cost, respectively, compared to 2.1% and 3.5% in the prior quarter.

However, the Company maintained that its “operating results and corresponding net asset value” were merely “impacted by company specific issues affecting four portfolio companies, each of which have been discussed on prior earnings calls.”

On this news, share prices fell $1.66 or 8.20% to close at $18.58 per share on August 7, 2025, on unusually heavy trading volume.

Then, on February 25, 2026, after the market closed, the Company announced fourth quarter and full year 2025 earnings, revealing net asset value had continued to decline to $20.89, down $1.10 or 5% from prior quarter, and the total fair value of investments fell another $406 million, to $13,009 million. Moreover, the Company reported earnings (loss) per share of negative $0.41, down $1.17 or 153.9% from the prior quarter, and a total net realized and unrealized loss per share of negative $0.89, down $1.08 or 568.421% from the prior quarter. Further, investments on non-accrual status again rose to 3.4% and 5.5% of the total investment portfolio at fair value and amortized cost, respectively, compared to 2.9% and 5.0% in the prior quarter. The Company also “acknowledge[d] specific challenges” with additional companies and cut its dividend to $0.48 per share (previously $0.70).

In the accompanying earnings call, the Company’s Chief Investment Officer was forced to acknowledge that its “recent underperformance reflects challenges in certain legacy investments” in addition to those previously discussed. Further, challenges ran much deeper, as the Company revealed issues with the identified companies only accounted for “50% of net realized and unrealized losses.

On this news, the Company’s stock price fell $2.03 or 15.24%, to close at $11.29 per share on February 26, 2026, on unusually heavy trading volume.

What Is The Lawsuit About?

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors: (1) the Company overstated the effectiveness of its portfolio restructuring efforts for its nonaccrual companies; (2) the Company overstated the valuation of its portfolio investments and/or overstated the effectiveness of the Company’s portfolio valuation process; (3) the Company overstated the durability of its quarterly distribution strategy; and (4) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Contact Us To Participate or Learn More:

If you purchased FS KKR Capital securities, wish to learn more about this action, or have any questions concerning this announcement or your rights or interests with respect to these matters, please click HERE or contact us at:

Law Offices of Frank R. Cruz
2121 Avenue of the Stars, Suite 800
Telephone: 310-914-5007
Email: info@frankcruzlaw.com
Visit our website at: www.frankcruzlaw.com

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Law Offices of Frank R. Cruz
2121 Avenue of the Stars, Suite 800
Telephone: 310-914-5007
Email: info@frankcruzlaw.com
Visit our website at: www.frankcruzlaw.com

The Law Offices of Frank R. Cruz 

NYSE:FSK

Release Summary
Law Offices of Frank R. Cruz Encourages FS KKR Capital Corp. (FSK) Shareholders To Inquire About Securities Fraud Class Action
Release Versions

Contacts

Law Offices of Frank R. Cruz
2121 Avenue of the Stars, Suite 800
Telephone: 310-914-5007
Email: info@frankcruzlaw.com
Visit our website at: www.frankcruzlaw.com

Social Media Profiles
More News From The Law Offices of Frank R. Cruz 

Securities Fraud Investigation Into GeneDx Holdings Corp. (WGS) Announced – Shareholders Who Lost Money Urged to Contact The Law Offices of Frank R. Cruz

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of GeneDx Holdings Corp. (“GeneDx” or the “Company”) (NASDAQ: WGS) on behalf of investors concerning the Company’s possible violations of federal securities laws.IF YOU ARE AN INVESTOR WHO LOST MONEY ON GENEDX HOLDINGS CORP. (WGS), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS.What Is the Investigation About?On May 4, 2026, after market hours, GeneDx released its first quarte...

Law Offices of Frank R. Cruz Encourages Regencell Bioscience Holdings Limited (RGC) Shareholders To Inquire About Securities Fraud Class Action

LOS ANGELES--(BUSINESS WIRE)--Law Offices of Frank R. Cruz Encourages Regencell Bioscience Holdings Limited (RGC) Shareholders To Inquire About Securities Fraud Class Action...

Deadline Soon: Soleno Therapeutics, Inc. (SLNO) Shareholders Who Lost Money Urged to Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming May 5, 2026 deadline to participate as a lead plaintiff in the securities fraud class action lawsuit filed on behalf of investors who acquired Soleno Therapeutics, Inc. (“Soleno” or the “Company”) (NASDAQ: SLNO) common stock between March 26, 2025 and November 4, 2026, inclusive (the “Class Period”). IF YOU ARE AN INVESTOR WHO LOST MONEY ON SOLENO THERAPEUTICS, INC. (SLNO), CLICK HERE TO PARTICIPATE...
Back to Newsroom